IL173065A - USE OF c-dI-GMP OR A CYCLIC DINUCLEOTIDE ANALOGUE THEREOF IN THE MANUFACTURE OF A MEDICAMENT, - Google Patents

USE OF c-dI-GMP OR A CYCLIC DINUCLEOTIDE ANALOGUE THEREOF IN THE MANUFACTURE OF A MEDICAMENT,

Info

Publication number
IL173065A
IL173065A IL173065A IL17306506A IL173065A IL 173065 A IL173065 A IL 173065A IL 173065 A IL173065 A IL 173065A IL 17306506 A IL17306506 A IL 17306506A IL 173065 A IL173065 A IL 173065A
Authority
IL
Israel
Prior art keywords
gmp
biofilm
microbial
colonization
aureus
Prior art date
Application number
IL173065A
Other languages
English (en)
Other versions
IL173065A0 (en
Original Assignee
David K R Karaolis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by David K R Karaolis filed Critical David K R Karaolis
Publication of IL173065A0 publication Critical patent/IL173065A0/en
Publication of IL173065A publication Critical patent/IL173065A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02Local antiseptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
IL173065A 2003-07-28 2006-01-10 USE OF c-dI-GMP OR A CYCLIC DINUCLEOTIDE ANALOGUE THEREOF IN THE MANUFACTURE OF A MEDICAMENT, IL173065A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49002903P 2003-07-28 2003-07-28
PCT/US2004/023498 WO2005030186A2 (en) 2003-07-28 2004-07-22 Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation

Publications (2)

Publication Number Publication Date
IL173065A0 IL173065A0 (en) 2006-06-11
IL173065A true IL173065A (en) 2011-05-31

Family

ID=34392905

Family Applications (1)

Application Number Title Priority Date Filing Date
IL173065A IL173065A (en) 2003-07-28 2006-01-10 USE OF c-dI-GMP OR A CYCLIC DINUCLEOTIDE ANALOGUE THEREOF IN THE MANUFACTURE OF A MEDICAMENT,

Country Status (7)

Country Link
US (1) US8367716B2 (enExample)
EP (1) EP1651242A2 (enExample)
JP (1) JP2007500697A (enExample)
AU (1) AU2004275696B2 (enExample)
CA (1) CA2533873A1 (enExample)
IL (1) IL173065A (enExample)
WO (1) WO2005030186A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1740192B1 (en) 2004-03-15 2012-06-13 David K. R. Karaolis Cyclic dinucleotide for stimulating the immune of inflammatory response
WO2006073514A2 (en) * 2004-08-25 2006-07-13 Tufts University Compositions, methods and kits for repressing virulence in gram positive bacteria
EP1782826A1 (en) * 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
US8343536B2 (en) 2007-01-25 2013-01-01 Cook Biotech Incorporated Biofilm-inhibiting medical products
BRPI0811530B1 (pt) 2007-05-14 2019-01-02 Research Foundation Of State Univ Of New York composição compreendendo indutor(es) de resposta fisiológica à dispersão ácido decanóico, superfície, solução, método ex vivo de tratamento ou inibição da formação de um biofilme sobre uma superfície
EP2254591B1 (en) 2008-02-08 2017-07-26 Prothera, Inc. Inhibition and treatment of gastrointestinal biofilms
WO2009133560A1 (en) * 2008-04-29 2009-11-05 Smart Assays Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof
EP2448954A1 (en) * 2009-07-01 2012-05-09 Rutgers, The State University of New Jersey Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof
CN102199183B (zh) * 2010-03-26 2013-12-18 北京大学 环二鸟苷酸及其类似物和制备方法
CN101843899B (zh) * 2010-05-24 2012-11-07 中国人民解放军第三军医大学 耐甲氧西林金黄色葡萄球菌(mrsa)重组多亚单位基因工程疫苗及其制备方法
WO2012021554A1 (en) * 2010-08-09 2012-02-16 Yale University Cyclic di-gmp-ii riboswitches, motifs, and compounds, and methods for their use
US8450293B2 (en) 2010-08-10 2013-05-28 Rutgers, The State University Of New Jersey Synthesis and characterization of C8 analogs of c-di-GMP
WO2013185052A1 (en) 2012-06-08 2013-12-12 Aduro Biotech Compostions and methods for cancer immunotherapy
EA201590396A1 (ru) 2012-12-13 2015-12-30 Адуро Биотек, Инк. Композиция, содержащая циклические пуриновые динуклеотиды с определенной стереохимией, и способ ее получения и применения
MX365661B (es) 2012-12-19 2019-06-10 Univ Texas Activacion farmaceutica de una senda de señalizacion de di-nucleotido ciclico de mamifero.
CN104152472A (zh) * 2012-12-28 2014-11-19 陶飞 一种双鸟苷酸环化酶基因、载体、工程菌及其应用
JP6153116B2 (ja) * 2013-01-09 2017-06-28 国立大学法人東北大学 トリアゾール連結型環状ジヌクレオチド類縁体
CA2908154C (en) 2013-04-29 2023-11-28 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
WO2014179760A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
JP6400082B2 (ja) * 2013-05-18 2018-10-03 アデュロ バイオテック,インコーポレイテッド 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を抑制するための組成物および方法
RS59500B1 (sr) 2013-05-18 2019-12-31 Aduro Biotech Inc Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
WO2015017652A1 (en) 2013-07-31 2015-02-05 Memorial Sloan-Kettering Cancer Center Sting crystals and modulators
US9315523B2 (en) 2013-12-06 2016-04-19 Rutgers, The State University Of New Jersey Cyclic dinucleosides
ES2692226T3 (es) 2014-06-04 2018-11-30 Glaxosmithkline Intellectual Property Development Limited Dinucleótidos cíclicos como moduladores de STING
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
HK1247089A1 (zh) 2015-03-10 2018-09-21 Aduro Biotech, Inc. 用於活化“干扰素基因刺激物”依赖性信号传导的组合物和方法
MX363780B (es) 2015-12-03 2019-04-03 Glaxosmithkline Ip Dev Ltd Dinucleótidos de purina cíclica como moduladores del estimulador de los genes de interferón.
CN114751950B (zh) 2016-03-18 2025-04-18 免疫传感器公司 环二核苷酸化合物及使用方法
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
MX2020002303A (es) 2017-08-30 2020-09-10 Beijing Xuanyi Pharmasciences Co Ltd Dinucleotidos ciclicos como moduladores del estimulador de genes de interferon.
PE20210156A1 (es) 2017-11-10 2021-01-26 Takeda Pharmaceuticals Co Compuestos moduladores de sting y metodos de elaboracion y uso
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
WO2020031083A1 (en) * 2018-08-06 2020-02-13 KHAN, Khalid Antimicrobial formulations comprising vancomycin or tobramycin
WO2020227421A1 (en) 2019-05-09 2020-11-12 Aligos Therapeutics, Inc. Modified cyclic dinucleoside compounds as sting modulators
CN114085887A (zh) * 2020-08-25 2022-02-25 中国科学院大连化学物理研究所 一种基于仿生微球的铜绿假单胞菌耐药浓度的检测方法
EP4240488A1 (en) 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Antibody drug conjugates
CN114099657B (zh) * 2021-11-04 2022-05-17 暨南大学 一种溶藻弧菌减毒活疫苗及其制备方法与应用
KR102551061B1 (ko) * 2022-05-26 2023-07-03 중앙대학교 산학협력단 Saha를 유효성분으로 포함하는 살모넬라 속 균주에 의한 바이오필름 생성 저해용 조성물
CN118956719B (zh) * 2024-07-31 2025-05-09 武汉市仪泰环境科技有限公司 一种毒性检测中加快微生物挂膜的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268274A (en) * 1989-04-12 1993-12-07 Cetus Corporation Methods and nucleic acid sequences for the expression of the cellulose synthase operon
AU1672492A (en) * 1991-05-03 1992-12-21 University Technologies International Inc. Biofilm reduction method
GB2257704B (en) 1991-07-18 1995-03-01 Erba Carlo Spa Cyclic oligonucleotides phosphorothioates
US20020091074A1 (en) * 2000-09-20 2002-07-11 Wooley Richard E. Medical compositions, dressings and methods for treating microbial infections of skin lesions
US20020169288A1 (en) * 2001-03-15 2002-11-14 Magnus Hook Collagen-binding adhesin from staphylococcus epidermidis and method of use
JP2002302404A (ja) * 2001-04-02 2002-10-18 Shiseido Co Ltd 抗菌防黴助剤
US7189351B2 (en) * 2001-10-25 2007-03-13 Spherix Incorporated D-tagatose as an anti-biofilm agent

Also Published As

Publication number Publication date
WO2005030186A2 (en) 2005-04-07
US8367716B2 (en) 2013-02-05
AU2004275696A1 (en) 2005-04-07
JP2007500697A (ja) 2007-01-18
WO2005030186A3 (en) 2005-07-14
EP1651242A2 (en) 2006-05-03
AU2004275696B2 (en) 2010-02-18
CA2533873A1 (en) 2005-04-07
US20070244059A1 (en) 2007-10-18
IL173065A0 (en) 2006-06-11

Similar Documents

Publication Publication Date Title
US8367716B2 (en) Method for attentuating virulence of microbial pathogens and for inhibiting microbial biofilm formation
Gaca et al. Adaptation to adversity: the intermingling of stress tolerance and pathogenesis in enterococci
Arias et al. The rise of the Enterococcus: beyond vancomycin resistance
Mitchell et al. Staphylococcus aureus sigma B-dependent emergence of small-colony variants and biofilm production following exposure to Pseudomonas aeruginosa 4-hydroxy-2-heptylquinoline-N-oxide
Sun et al. Fatty acids regulate stress resistance and virulence factor production for Listeria monocytogenes
Fernández et al. Creeping baselines and adaptive resistance to antibiotics
Qin et al. Identification of transposon insertion mutants of Francisella tularensis tularensis strain Schu S4 deficient in intracellular replication in the hepatic cell line HepG2
Honma et al. Role of a Tannerella forsythia exopolysaccharide synthesis operon in biofilm development
Martinez Mechanisms of action and of resistance to quinolones
Boddey et al. The bacterial gene lfpA influences the potent induction of calcitonin receptor and osteoclast‐related genes in Burkholderia pseudomallei‐induced TRAP‐positive multinucleated giant cells
Bartoli et al. Mutability in P seudomonas viridiflava as a programmed balance between antibiotic resistance and pathogenicity
Jolivet‐Gougeon et al. Bacterial Persistence in Biofilms and Antibiotics: Mechanisms Involved
Wagley et al. A proteasome inhibitor produced by Burkholderia pseudomallei modulates intracellular growth
Padilla et al. In vitro antibacterial activity of the peptide PsVP-10 against Streptococcus mutans and Streptococcus sobrinus with and without glycocalyx
Ravishankar Investigation of antibiofilm and antivirulence activity of 5-fluorocytosine in Escherichia coli
Kanwar et al. Oral Microbiome and Drug Resistance
Rothstein et al. Rifalazil retains activity against rifampin-resistant mutants of Chlamydia pneumoniae
Thapa From Regulation of Secondary Metabolites to Increased Virulence Under Sublethal Dosage of Antibiotics: An Unprecedented Role of Global Regulator, MftR, in Burkholderia Thailandensis
Ih Mechanisms and PK/PD modelling of MCR-1-induced adaptive resistance in Enterobacteriaceae
Scoffone et al. Antimicrobial drug efflux pumps in Burkholderia
Dapa Biofilm formation by the anaerobic pathogen Clostridium difficile
Plume Characterising a novel heavy metal-sensing multikinase network in the environmental organism and opportunistic pathogen, Burkholderia cenocepacia
Kar et al. Quorum sensing mediated attenuation of biofilm formation and virulence traits in Staphylococcus aureus by trigonelline
Reynolds Cyclic di-GMP Regulates Motility, Biofilm Formation, and Desiccation Tolerance in Acinetobacter baumannii
Oberkampf et al. c-di-AMP signaling is required for bile salts resistance and long-term colonization by Clostridioides difficile

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed